Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics
about
Clinical Implications of Antiviral Resistance in InfluenzaInfluenza treatment and prophylaxis with neuraminidase inhibitors: a reviewInfluenza prevention and treatment in transplant recipients and immunocompromised hostsNew small-molecule drug design strategies for fighting resistant influenza AThe pharmacological management of severe influenza infection - 'existing and emerging therapies'.Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice.Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical managementHow I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantationThe application of absolute quantitative (1)H NMR spectroscopy in drug discovery and development.Influenza RNA-Dependent RNA Polymerase (RdRp) Inhibitors: Potential New Therapy for Influenza Treatment.A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir.Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Inhibitory effects and related molecular mechanisms of total flavonoids in Mosla chinensis Maxim against H1N1 influenza virus.Chromatography column comparison and rapid pretreatment for the simultaneous analysis of amantadine, rimantadine, acyclovir, ribavirin, and moroxydine in chicken muscle by ultra high performance liquid chromatography and tandem mass spectrometry.Investigating Different Mechanisms of Action in Combination Therapy for Influenza
P2860
Q26782746-89AF7C88-557F-4C9E-AE29-915A808EFADFQ26860032-9A0EA6C2-5F9D-4A53-9B5B-7AA4D116F8FAQ27011595-EA234C55-B2C5-4E94-A3F5-9BF1C1085D16Q28080554-243FE6F8-F249-4874-859F-A675DD6097FDQ30243907-0571FA7E-4235-4B2A-A62E-8A579BCDAB6BQ30359363-00AE100F-6E3F-470F-92D4-6435C0B6F78CQ30368680-B058151E-7E87-4EA7-A23C-9AA66BC2CD1CQ36965855-BAAAB5C9-82DC-4FDD-B0EA-EF3D024CDA6CQ38836228-31EA70B4-37C8-45BF-B8B1-71820181C265Q39777631-5BFBF1E2-1B24-442C-ADB8-D5727DE1E4B6Q40065607-D09B0468-335E-438B-99EF-753AD1108735Q41011707-09C77414-7448-4D35-81CA-2BDE9AC1AB6DQ41928469-97BD528C-BB38-487E-9ABE-E9D564F4E6D9Q43280688-7D87E485-B1ED-4C75-9198-D5D7D77F9CA3Q45324213-B8643650-B16E-4518-AFAE-2EB5C7C149C4Q48972661-4D1340A8-6887-4CFD-813B-2B253CD47F89Q58573517-BF2634A5-192A-497E-87C2-E528A372F038
P2860
Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 December 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination therapy with amant ...... n: safety and pharmacokinetics
@en
Combination therapy with amant ...... : safety and pharmacokinetics.
@nl
type
label
Combination therapy with amant ...... n: safety and pharmacokinetics
@en
Combination therapy with amant ...... : safety and pharmacokinetics.
@nl
prefLabel
Combination therapy with amant ...... n: safety and pharmacokinetics
@en
Combination therapy with amant ...... : safety and pharmacokinetics.
@nl
P2093
P2860
P356
P1433
P1476
Combination therapy with amant ...... n: safety and pharmacokinetics
@en
P2093
Christian Renaud
Gregory T Went
Jack T Nguyen
Janet A Englund
Menno D de Jong
Michael J Boeckh
Niklas Lindegardh
Paul A Tambyah
Sachiko Seo
P2860
P304
P356
10.3851/IMP2475
P577
2012-12-21T00:00:00Z